Vivet Therapeutics

Executive Summary

Vivet Therapeutics is a French biotechnology company pioneering gene therapies for rare liver disorders using adeno-associated virus (AAV) vectors. Founded in 2016, the company addresses a critical barrier in gene therapy—pre-existing neutralizing antibodies—through its proprietary platform designed to enable treatment access for previously ineligible patients. Vivet's lead candidate targets diseases with high unmet need, such as Wilson disease, utilizing a single-dose approach aimed at durable correction of the underlying genetic defect. The company's technology has shown promising preclinical and early clinical results, positioning it as a potential leader in the liver gene therapy space. Currently in Phase 3 development, Vivet is advancing its lead product toward pivotal trials while expanding its pipeline to include additional rare liver conditions. The company's ability to overcome neutralizing antibodies could significantly expand the treatable patient population, offering a competitive advantage in the gene therapy landscape. With a strong scientific foundation and a clear regulatory path, Vivet is poised to address significant unmet medical needs. Key upcoming milestones include the initiation of a Phase 3 trial and potential financing events to support late-stage development, making the company an attractive prospect for investors interested in gene therapy innovation.

Upcoming Catalysts (preview)

• H2 2026Initiation of Phase 3 trial for lead candidate in Wilson disease75% success
• 2026Financing round to fund pivotal development80% success
• Q3 2026Clinical data update from ongoing Phase 1/2 studies70% success